Zoek een klinische studie of trial
Andere zoekoptie(s)
9 Resultaat/Resultaten
Aanwerving proef
= 
; Lopend onderzoek
= 
; Terminated trial
= 
; Gefinancierd door een IRDiRC-lid = 
; Lid van een ERN = 
Nationale klinische studie(s)
BELGIË
LIEGE
LIEGE
ePHex OLE: An open-label single-arm treatment extension study to evaluate the long-term efficacy and safety of Oxabact® for patients with primary hyperoxaluria who completed study OC5-DB-02 - BE
CHU de Liège - Site du Sart Tilman
Néphrologie
DUITSLAND
Nordrhein-Westfalen
BONN
OC5-OL-01: A Phase 2 Open-label Multi-centre Study to Evaluate the Efficacy and Safety of Oxabact® to Reduce Plasma Oxalate in Subjects With Primary Hyperoxaluria Who Are on Dialysis - DE
Kindernierenzentrum Bonn
DUITSLAND
Nordrhein-Westfalen
BONN
Phase 1/2 Oxabact OC5 study: A Phase 1/2, randomised, placebo-controlled, double-blind, multicentre study to evaluate the efficacy and safety of OC5 to reduce urinary oxalate in subjects with Primary Hyperoxaluria - DE - Completed
Universitäts-Kinderklinik Bonn
Abteilung für allgemeine Pädiatrie und Poliklinik
DUITSLAND
Nordrhein-Westfalen
BONN
ePHex OLE: An open-label single-arm treatment extension study to evaluate the long-term efficacy and safety of Oxabact® for patients with primary hyperoxaluria who completed study OC5-DB-02 -DE
Universitäts-Kinderklinik Bonn
Abteilung für allgemeine Pädiatrie und Poliklinik
SPANJE
Cataluña
BARCELONA
ePHex-OLE: An open-label single-arm treatment extension study to evaluate the long-term efficacy and safety of Oxabact® for patients with primary hyperoxaluria who completed study OC5-DB-02 - ES (completed)
Hospital Universitari Vall d'Hebron
Servicio de Nefrología
SPANJE
Cataluña
BARCELONA
A phase III double-blind, randomized study to evaluate the long-term efficacy and safety of Oxabact® in patients with primary hyperoxaluria - ES (completed)
Hospital Universitari Vall d'Hebron
Servicio de Nefrología
VERENIGD KONINKRIJK
Greater London
LONDON
ePHex OLE: An Open-label Single-arm Treatment Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact for Patients With Primary Hyperoxaluria Who Completed Study OC5-DB-02-GB
Royal Free London Hospital
University College London, Centre for Nephrology
VERENIGD KONINKRIJK
West Midlands
BIRMINGHAM
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multi-center, International Study to Evaluate the Efficacy and Safety of OxabactTM to Reduce Urinary Oxalate in Subjects With Primary Hyperoxaluria
Birmingham Children's Hospital NHS Foundation Trust
Birmingham Children's Hospital
VERENIGD KONINKRIJK
West Midlands
BIRMINGHAM